0000000000155168

AUTHOR

Hao Y

showing 2 related works from this author

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

2017

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, …

0301 basic medicine030204 cardiovascular system & hematologylaw.invention0302 clinical medicinec-reactive proteinRandomized controlled triallawCardiovascular Diseasemiddle ageddouble-blind methodantibodiesMyocardial infarctionhumansStrokeinterleukin-1betabiologyAntibodies MonoclonaldrugGeneral MedicineLipidAged; anti-inflammatory agents; antibodies; monoclonal; antibodies; monoclonal; humanized; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship; drug; double-blind method; female; humans; incidence; infections; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; strokestrokeAnti-Inflammatory AgentagedEditorialfemalemyocardial infarctionAtherosclerosiMonoclonalsecondary preventionHumanmedicine.drugmedicine.medical_specialtymonoclonalNeutropeniaAntibodies Monoclonal HumanizedInfectionsPlaceboaged; anti-inflammatory agents; antibodies monoclonal; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship drug; double-blind method; female; humans; incidence; infection; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; stroke; medicine (all)anti-inflammatory agentsdose-response relationshiplipids03 medical and health sciencesmaleInternal medicinemedicineneutropeniamedicine (all)Dose-Response Relationship Drugbusiness.industryAntiinflammatory Therapy Canakinumab for Atherosclerotic DiseaseC-reactive proteinmedicine.diseaseinfectioncardiovascular diseasesSurgeryCanakinumab030104 developmental biologyincidencebiology.proteinatherosclerosisbusinessNew England journal of medicine
researchProduct

Carga global, regional y nacional de neurológicas. Desórdenes, 1990-2016: un análisis sistemático para el Global Estudio de la carga de enfermedad 20…

2019

Publisher´s version (útgefin grein).

DánarmeinMaleEpidemiologyDiseasesMalalties cerebralsGlobal Burden of DiseaseDisability Evaluation0302 clinical medicineCase fatality ratePsychologyKonurCause of deathAged 80 and overeducation.field_of_studyIncidenceMenTaugavísindiddc:3. Good healthSálfræðiWorld healthMuerteNeurologyGBD 2016 Neurology CollaboratorsBrain diseasesQuality-Adjusted Life YearsAlzheimer diseaseCarga global de enfermedadesNervous systemmedicine.medical_specialtyGlobal burden of diseasesLífsgæðiArticle03 medical and health sciencesHealth SciencesHumansWomeneducationTrastornos neurológicosVLAGAgedScience & Technology3112 NeurosciencesGlobal Burden of Diseases030104 developmental biologyYears of potential life lostΕπιστήμες ΥγείαςDementiaHuman medicineNeurosciences & NeurologyNeurology (clinical)Clinical Medicine1109 NeurosciencesNeurological disorders030217 neurology & neurosurgerydementiaRC0301 basic medicinePediatricsDánartíðniNutrition and Disease3124 Neurology and psychiatryDisease StudyTaugasjúkdómarRisk FactorsVoeding en ZiekteCause of DeathGlobal healthPrevalenceNeurological disorders; Global Burden of DiseasesCauses of deathPublic healthMortality rateMental DisordersAge FactorsPublic Health Global Health Social Medicine and EpidemiologyMiddle Agedneurologic diseaseDeathLýðheilsaFemaleLife Sciences & BiomedicineQuality of lifeAdultPopulationClinical NeurologySex FactorsmedicineLife ScienceDisability-adjusted life year:Medicine [Science]MortalityPsychiatryDisease burdenNeurology & Neurosurgeryburden of neurological disordersFaraldsfræðibusiness.industryKlinisk medicinCauses de la mort1103 Clinical SciencesFolkhälsovetenskap global hälsa socialmedicin och epidemiologiSocioeconomic FactorsKarlarglobal disease burdenNervous System DiseasesCause of death/trendsbusiness
researchProduct